XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.20 and traded as high as $2.64. XORTX Therapeutics shares last traded at $2.44, with a volume of 32,581 shares.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.
View Our Latest Analysis on XRTX
XORTX Therapeutics Stock Up 9.9%
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last announced its quarterly earnings data on Saturday, August 15th. The technology company reported ($1.05) EPS for the quarter.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in XORTX Therapeutics stock. Citadel Advisors LLC increased its position in shares of XORTX Therapeutics Inc. (NASDAQ:XRTX – Free Report) by 124.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,326 shares of the technology company’s stock after purchasing an additional 47,858 shares during the period. Citadel Advisors LLC owned 1.24% of XORTX Therapeutics worth $70,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.23% of the company’s stock.
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers.
Further Reading
- Five stocks we like better than XORTX Therapeutics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
